Polyrizon Ltd. (PLRZ)
NASDAQ: PLRZ · Real-Time Price · USD
16.00
-0.63 (-3.79%)
At close: Apr 28, 2026, 4:00 PM EDT
16.50
+0.50 (3.13%)
After-hours: Apr 28, 2026, 4:22 PM EDT
Company Description
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel.
The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients.
It also develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza blockers.
Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.
Polyrizon Ltd.
| Country | Israel |
| Founded | 2005 |
| IPO Date | Oct 29, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Tomer Izraeli |
Contact Details
Address: 5 Ha-Tidhar Street Ra'anana, 4366507 Israel | |
| Phone | 972 9 374 0120 |
| Website | polyrizon-biotech.com |
Stock Details
| Ticker Symbol | PLRZ |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.38 |
| CIK Code | 0001893645 |
| CUSIP Number | M79549123 |
| ISIN Number | IL0011814113 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Tomer Izraeli | Founder, Chief Executive Officer and Director |
| Nir Ben Yosef | Chief Financial Officer and Compliance Officer |
| Dr. Tidhar Turgeman | Chief Technology Officer |
| Dr. Eyal S. Ron Ph.D. | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2026 | 6-K | Report of foreign issuer |
| Apr 23, 2026 | D | Notice of Exempt Offering of Securities |
| Apr 23, 2026 | F-1 | Registration statement for certain foreign private issuers |
| Apr 8, 2026 | 6-K | Report of foreign issuer |
| Apr 8, 2026 | 424B5 | Filing |
| Mar 27, 2026 | 20-F/A | Filing |
| Mar 25, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Mar 17, 2026 | 6-K | Report of foreign issuer |
| Mar 16, 2026 | SCHEDULE 13G | Filing |
| Mar 10, 2026 | 6-K | Report of foreign issuer |